Drugs / Methamphetamine

Regulatory milestones approvals, filings & regulatory actions · 1 recorded

MilestoneJurisdictionBrandIndicationDateSentence it was read from
Approved US (FDA) DESOXYN 1943-12-31 fda.gov

Trials 16 · a red edge is where a trial was stopped

1942194319441945194619471948194919501951195219531954195519561957195819591960196119621963196419651966196719681969197019711972197319741975197619771978197919801981198219831984198519861987198819891990199119921993199419951996199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023202420252026202720282029203020312032
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 05 trials
Phase 0 NCT05379959 May → Oct 2022 substance abuse University of Chicago Completed No outcome recorded
Phase 0 NCT05003076 Jul 2021 → Apr 2023 University of Chicago Completed No outcome recorded
Phase 0 NCT04642820 Nov 2020 → Oct 2023 substance abuse University of Chicago Completed No outcome recorded
Phase 0 NCT02058966 Jun 2014 → Jun 2016 methamphetamine dependence Oregon Health and Science University Completed No outcome recorded
Phase 0 NCT01967381 Oct 2013 → Sep 2018 methamphetamine dependence, substance abuse University of Kentucky Completed No outcome recorded
Phase 15 trials
Phase 1 NCT06746831 Jul 2026 → Mar 2028 expected substance-related disorder University of Wisconsin, Madison Not yet recruiting No outcome recorded
Phase 1 NCT04614584 May 2021 → May 2024 methamphetamine dependence San Francisco Department of Public Health Completed No outcome recorded
Phase 1 NCT03106571 Aug 2017 → Jul 2020 methamphetamine dependence University of California, Los Angeles Terminated No outcome recorded
Phase 1 NCT03790618 Jun 2016 → Aug 2018 University of Chicago Completed No outcome recorded
Phase 1 NCT01843205 Apr 2013 → Mar 2017 amphetamine abuse, methamphetamine dependence University of Kentucky Completed No outcome recorded
Phase 21 trial
Phase 2 NCT03226223 Sep 2016 → Jul 2019 amphetamine abuse New York State Psychiatric Institute Completed No outcome recorded
Phase 44 trials
Phase 4 NCT07584369 Jul 2026 → Jul 2029 expected HIV infectious disease, substance-related disorder University of California, San Francisco Not yet recruiting No outcome recorded
Phase 4 NCT03825536 Jan 2021 → Jan 2023 HIV infectious disease, methamphetamine dependence University of California, San Francisco Completed No outcome recorded
Phase 4 NCT03973489 Aug 2019 → Mar 2023 methamphetamine dependence Oregon Health and Science University Completed No outcome recorded
Phase 4 NCT01529892 Amobarbital, deficient N-hydroxylation of California Pacific Medical Center Research Institute Withdrawn No outcome recorded
Phase not applicable1 trial
NCT02323048 Jul → Nov 2014 substance abuse University of Chicago Completed No outcome recorded
Also used as a comparator or background therapy in 3 trials
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 01 trial
Phase 0 NCT06989853 Background Aug 2025 → Feb 2029 expected methamphetamine dependence William Stoops Recruiting No outcome recorded
Phase 11 trial
Phase 1 NCT04178993 Comparator Sep 2019 → May 2021 methamphetamine dependence Craig Rush Completed No outcome recorded
Phase 21 trial
Phase 2 NCT05783817 Comparator Sep 2025 → Dec 2026 expected obsessive-compulsive disorder Carolyn Rodriguez Recruiting No outcome recorded

Evidence & citations 21 cited values

Every value below carries the sentence it was read from. 20 sources stand behind the page.

FieldValueCited text
Known as Methamphetamine ClinicalTrials.gov intervention name — accepted as the source's own label NCT06989853
17

NCT04614584

NCT04642820

NCT03825536

NCT01967381

NCT02058966

NCT05783817

NCT02323048

NCT01529892

NCT03973489

NCT03226223

NCT07584369

NCT03790618

NCT03106571

NCT05379959

NCT01843205

NCT05003076

NCT04178993

Known as (s)-phenylmethylaminopropane ChEMBL registry synonym — accepted as the source's own label CHEMBL1201201
Known as Desoxyn “The research proposed in this application will determine the initial efficacy, safety and tolerability of a novel drug combination, oxazepam (Serax®) and naltrexone (Revia®),...” NCT01967381
1

“Twenty milligrams of MA (Desoxyn; Lundbeck Inc) tablets will be crushed and placed in 10 ml of Ora-Sweet syrup.” NCT02323048

Known as J6.362B ChEMBL registry synonym — accepted as the source's own label CHEMBL1201201
Known as Metamfetamine ChEMBL registry synonym — accepted as the source's own label CHEMBL1201201
Known as Metamfetamine hydrochloride ChEMBL registry synonym — accepted as the source's own label CHEMBL1201201
Known as Metamphetamine ChEMBL registry synonym — accepted as the source's own label CHEMBL1201201
Known as Metamphetamine hydrocloride ChEMBL registry synonym — accepted as the source's own label CHEMBL1201201
Known as Metanfetamina ChEMBL registry synonym — accepted as the source's own label CHEMBL1201201
Known as Methampex ChEMBL registry synonym — accepted as the source's own label CHEMBL1201201
Known as Methamphetamine hcl ChEMBL registry synonym — accepted as the source's own label CHEMBL1201201
Known as METHAMPHETAMINE HYDROCHLORIDE ChEMBL registry synonym — accepted as the source's own label CHEMBL1201201
Known as Methamphetamine hydrochloride cii ChEMBL registry synonym — accepted as the source's own label CHEMBL1201201
Known as Methylamfetamine hydrochloride ChEMBL registry synonym — accepted as the source's own label CHEMBL1201201
Known as NSC-169505 ChEMBL registry synonym — accepted as the source's own label CHEMBL1201201
Known as NSC-25115 ChEMBL registry synonym — accepted as the source's own label CHEMBL1201201
Known as S-(+)-methamphetamine ClinicalTrials.gov intervention name — accepted as the source's own label NCT06746831
Action Activate “MA is a potent agonist at the TAAR1 receptor” NCT03973489
Modality Small molecule CHEMBL1201201
Route Oral “a modest oral dose of 5 milligrams of methamphetamine” NCT01529892
Target TAAR1 “MA is a potent agonist at the TAAR1 receptor” NCT03973489